drugset / Trial / NCT03807063
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Phase 1
Withdrawn
Fred Hutchinson Cancer Center
Bellicum Pharmaceuticals · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of rivogenlecleucel, and how well it works, in treating patients with blood cancer that has come back (recurrent) after stem cell transplant. Donor T-cell therapy (rivogenlecleucel) may help control transplant-related infections after stem cell transplant.
Timeline
- Start
- 2020-01-02
- Primary completion
- 2020-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rivogenlecleucel | Cell therapy | — | Intravenous |
| Background | Rimiducid | Other / unclassified | — | Intravenous |